BTK and B-cell chronic lymphocytic leukemia: Inhibiting BTK has yielded remarkable gains for patients with B-cell malignancies, and the development of pirtobrutinib furthers these gains by introducing a new treatment option for patients with CLL/SLL, MCL, and other lymphomas.